Difference between revisions of "Team:UCC Ireland"
| (4 intermediate revisions by 2 users not shown) | |||
| Line 36: | Line 36: | ||
<a class="dropdown-toggle" data-toggle="dropdown" role="button" aria-haspopup="true" aria-expanded="false">Project<span class="caret"></span></a> | <a class="dropdown-toggle" data-toggle="dropdown" role="button" aria-haspopup="true" aria-expanded="false">Project<span class="caret"></span></a> | ||
<ul class="dropdown-menu"> | <ul class="dropdown-menu"> | ||
| − | |||
<li><a href="https://2016.igem.org/Team:UCC_Ireland/Limitless_Lactis">Limitless Lactis</a></li> | <li><a href="https://2016.igem.org/Team:UCC_Ireland/Limitless_Lactis">Limitless Lactis</a></li> | ||
| − | <li><a href="https://2016.igem.org/Team:UCC_Ireland/iRFP">iRFP In- | + | <li><a href="https://2016.igem.org/Team:UCC_Ireland/iRFP">iRFP In-Vitro Reporter</a></li> |
<li><a href="https://2016.igem.org/Team:UCC_Ireland/Leishmaniasis">Leishmaniasis</a></li> | <li><a href="https://2016.igem.org/Team:UCC_Ireland/Leishmaniasis">Leishmaniasis</a></li> | ||
<li><a href="https://2016.igem.org/Team:UCC_Ireland/Proof">Proof</a></li> | <li><a href="https://2016.igem.org/Team:UCC_Ireland/Proof">Proof</a></li> | ||
| Line 58: | Line 57: | ||
<li><a href="https://2016.igem.org/Team:UCC_Ireland/Parts">Parts</a></li> | <li><a href="https://2016.igem.org/Team:UCC_Ireland/Parts">Parts</a></li> | ||
<li class="dropdown"> | <li class="dropdown"> | ||
| − | <a class="dropdown-toggle" data-toggle="dropdown" role="button" aria-haspopup="true" aria-expanded="false">Collaborations <span class="caret"></span></a> | + | <a class="dropdown-toggle" data-toggle="dropdown" role="button" aria-haspopup="true" aria-expanded="false">Collaborations<span class="caret"></span></a> |
<ul class="dropdown-menu"> | <ul class="dropdown-menu"> | ||
<li><a href="https://2016.igem.org/Team:UCC_Ireland/Collaborations">iGEM Teams</a></li> | <li><a href="https://2016.igem.org/Team:UCC_Ireland/Collaborations">iGEM Teams</a></li> | ||
| Line 65: | Line 64: | ||
<li><a href="https://2016.igem.org/Team:UCC_Ireland/Application_Scenario">Application Scenario</a></li> | <li><a href="https://2016.igem.org/Team:UCC_Ireland/Application_Scenario">Application Scenario</a></li> | ||
<li><a href="https://2016.igem.org/Team:UCC_Ireland/Techno_Moral_Newsletter">Techno-Moral Newsletter</a></li> | <li><a href="https://2016.igem.org/Team:UCC_Ireland/Techno_Moral_Newsletter">Techno-Moral Newsletter</a></li> | ||
| − | <li><a href="https://2016.igem.org/Team:UCC_Ireland/ | + | <li><a href="https://2016.igem.org/Team:UCC_Ireland/Blog.html">Techno-Moral Blog</a></li> |
</ul> | </ul> | ||
</li> | </li> | ||
| Line 80: | Line 79: | ||
<div class="col-xs-12 col-md-12"> | <div class="col-xs-12 col-md-12"> | ||
| − | <img style="width: | + | <img style="width: 400px; display:block; margin:auto;" src="https://static.igem.org/mediawiki/2016/6/6b/T--UCC_Ireland--LIMITLESSLACTIS-BLACK.png" alt=""> |
| − | + | ||
| − | + | ||
| − | + | ||
</div> | </div> | ||
</div><!-- /landing --> | </div><!-- /landing --> | ||
| Line 93: | Line 90: | ||
<hr> | <hr> | ||
<p class="lead text-left"> | <p class="lead text-left"> | ||
| − | <em>Lactococcus lactis</em>, a generally recognised as safe (GRAS) bacterium commonly used in food production, is highly amenable to genetic manipulation. We aim to develop a synthetic L. lactis-based platform that can deliver proteins to immune cells to precisely influence the host immune response for use in the treatment of various diseases. Potential applications which we have investigated include vaccination strategies and macrophage modification. We have developed the platform as a vaccine against leishmaniasis, a neglected tropical disease increasing in geographical distribution. LJM11 is an immunogenic salivary protein of the sandfly vector, Lutzomyia longipalpis. Our inexpensive platform, through simple oral administration, has the capacity to deliver this protein to antigen-presenting cells, and potentially immunise against the life cycle of leishmaniasis. Besides vaccination strategies, this platform may be employed to modify the phenotype of other phagocytic cells associated with diseases such as cancer. | + | <em>Lactococcus lactis</em>, a generally recognised as safe (GRAS) bacterium commonly used in food production, is highly amenable to genetic manipulation. We aim to develop a synthetic <em>L. lactis</em>-based platform that can deliver proteins to immune cells to precisely influence the host immune response for use in the treatment of various diseases. Potential applications which we have investigated include vaccination strategies and macrophage modification. We have developed the platform as a vaccine against leishmaniasis, a neglected tropical disease increasing in geographical distribution. LJM11 is an immunogenic salivary protein of the sandfly vector, <em>Lutzomyia longipalpis</em>. Our inexpensive platform, through simple oral administration, has the capacity to deliver this protein to antigen-presenting cells, and potentially immunise against the life cycle of leishmaniasis. Besides vaccination strategies, this platform may be employed to modify the phenotype of other phagocytic cells associated with diseases such as cancer. |
</p> | </p> | ||
<hr> | <hr> | ||
Latest revision as of 00:07, 20 October 2016
Limitless Lactis: Intelligent Lactococcus lactis strains as a protein delivery platform for disease treatment.
Lactococcus lactis, a generally recognised as safe (GRAS) bacterium commonly used in food production, is highly amenable to genetic manipulation. We aim to develop a synthetic L. lactis-based platform that can deliver proteins to immune cells to precisely influence the host immune response for use in the treatment of various diseases. Potential applications which we have investigated include vaccination strategies and macrophage modification. We have developed the platform as a vaccine against leishmaniasis, a neglected tropical disease increasing in geographical distribution. LJM11 is an immunogenic salivary protein of the sandfly vector, Lutzomyia longipalpis. Our inexpensive platform, through simple oral administration, has the capacity to deliver this protein to antigen-presenting cells, and potentially immunise against the life cycle of leishmaniasis. Besides vaccination strategies, this platform may be employed to modify the phenotype of other phagocytic cells associated with diseases such as cancer.
